Hologic loses $4M patent suit to Smith & Nephew over Interlace fibroid tech

Wed, 09/05/2012 - 8:55pm
Mass Device

Hologic says a Massachusetts jury ruled against it in a patent infringement lawsuit, awarding damages of $4 million over the MyoSure device Hologic acquired along with Interlace Medical.

SNN, Interlace logos

A Massachusetts jury handed Hologic (NSDQ:HOLX) a $4 million setback today in a patent infringement battle with Smith & Nephew (FTSE:SN, NYSE:SNN) over Hologic's MyoSure fibroid surgery device.

The Bedford, Mass.-based women's health giant bought the lawsuit along with Interlace Medical for $125 million in early 2011. Interlace developed the MyoSure device, a hysteroscopic system designed to remove fibroids — benign tumors of the uterus — in an out-patient procedure, using a high-speed cutting blade.

The lawsuit, the consolidation of two cases filed by the British orthopedic devices giant against Interlace and then Hologic, alleges infringement of a pair of patents covering the MyoSure technology.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.